SFOSF News and Press, Shanghai Fosun Pharmaceutical Co. Ltd. From 09/21/22

Summary Fosun has sold down its stake in New China Life, its latest move to raise cash as it faces large debt maturing in the next 12 months. The company is also selling down stakes in its Fosun Tourism unit, owner of the Club Med resort chain, and appears to be selling shares in ...

China's National Medical Products Administration (NMPA) granted conditional approval to the country's first home made COVID antiviral pill Azvudine developed by Genuine Biotech which was previous approved to treat HIV. The Chinese drug regulator approved the Henan-base...

Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. OnCusp Therapeutics, a New York-Shanghai biopharma, acquired global rights (ex-China) to a pre-clinical CDH6 antibody drug conjugate from Multitude Th...

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...

A group of generic drug manufacturers agreed to make versions of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid at under US$25 per treatment course, The Clinton Health Access Initiative (CHAI) announced on Thursday. The health organization did not disclose the names of the drugmakers ...

German vaccine developer, BioNTech (NASDAQ:BNTX) has completed a Phase 2 study for the company’s blockbuster COVID-19 vaccine in China in January, but has yet to post results, Reuters reported on Tuesday citing a registry of clinical trials. BioNTech (BNTX) has partnered...

Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million. Fosun Pharma’s revenue and profit both rose around 30% last year as Covid-19 vaccines and stake sales in its sub...

Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen’s Bavarian Nordic in a $225 million deal. Beijing YishengBio completed a $40 million Series C round in a royalty-based transaction with R-Bridge, a ...

Medicines Patent Pool (MPP) announced on Thursday that nearly three dozen companies signed agreements to manufacture the generic versions of the oral COVID-19 therapy developed by Pfizer (NYSE:PFE). The sublicence agreements follow a voluntary licensing agreement signed by MPP and Pfizer (PFE...

Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in vaccine company Chengdu Antejin Biotech. Shanghai Pharma subsidiary SPH SINE acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. Suzhou Innovent and ...